Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

Tack, Jan; Stanghellini, Vincenzo; Mearin, Fermı́n; Yiannakou, Yan; Layer, Peter; Coffin, Benoït; Simrén, Magnus; Mackinnon, J; Wiseman, Gwen; Marciniak, A

doi:10.1186/s12876-019-0985-1

Cited by 76 publications

(72 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The direct cost EUR 4,282 can be compared with data published by the Swedish Association of Local Authorities and Regions, wherein they reported an annual healthcare direct cost of EUR 1,951 for an average female Swede. Our total annual cost of EUR 8,768/woman can also be compared with other recent Swedish studies reporting annual costs in other benign persistent conditions: annual total cost of migraine was EUR 10,790 (EUR rate 2013) per patient [22], annual total cost of Irritable bowel syndrome with predominant constipation was EUR 12,873 (EUR rate 2019) per patient [23], and mean total cost of low back pain was EUR 2,753 (EUR rate 2016) per episode [24].…”

Section: Discussionmentioning

confidence: 71%

Healthcare Consumption and Cost Estimates Concerning Swedish Women with Endometriosis

Grundström

Spagnoli

Lövqvist

et al. 2020

Gynecol Obstet Invest

View full text Add to dashboard Cite

Introduction: Endometriosis is known for its substantial effect on women’s wellbeing and quality of life. In order to evaluate disease burden, treatments and health services, assessments of healthcare consumption and cost estimates are necessary. Objectives: The aim of this study was to estimate healthcare consumption and annual cost per woman with endometriosis in Sweden and to examine healthcare consumption and costs in different age groups. Methods: A questionnaire was distributed to 400 members of the Endometriosis Association and to 400 randomly selected women with surgically confirmed endometriosis. Official statistics were obtained via correspondence, publications, and database searches. Results: Analysis of the 431 returned questionnaires showed that women under 30 years utilized more inpatient and outpatient care than older women. The mean annual cost among all women was EUR 8,768/woman. The direct healthcare cost of managing the disease was EUR 4,282, while the indirect cost was EUR 4,486. Absence from work was reported by 32% of the women, while 36% reported reduced time at work because of endometriosis. Conclusion: Our results confirm the substantial negative effect of endometriosis upon women’s lives and their relatively high healthcare consumption.

show abstract

Section: Discussionmentioning

confidence: 71%

Healthcare Consumption and Cost Estimates Concerning Swedish Women with Endometriosis

Grundström

Spagnoli

Lövqvist

et al. 2020

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Further investigation is needed to determine the prevalence and relevance of the range of functional gastrointestinal disorders in patients with fibromyalgia. 3 Background Both functional gastrointestinal disorders (FGID) and fibromyalgia are poorly understood syndromes significantly impacting quality of life (1) and imposing substantial financial burden (2, 3) with healthcare-associated costs reaching quadruple that of a reference population (4). Both syndromes are considered attributable to sympathetic dysfunction (5) resulting in central sensitisation (6) and were recently categorised as "Central Sensitivity Syndromes" (7,8).…”

Section: Resultsmentioning

confidence: 99%

A systematic review of the association between fibromyalgia and functional gastrointestinal disorders

Erdrich¹

2020

Preprint

View full text Add to dashboard Cite

Background Fibromyalgia and functional gastrointestinal disorders are frequently encountered in clinical settings. Common to both is significant burden on individuals and health care systems, an elusive aetiology and several comorbid conditions. While a relationship between irritable bowel syndrome and fibromyalgia has been demonstrated, a broader review of the relationship between fibromyalgia and other functional gut disorders has not been undertaken. Objectives This paper reports a systematic review of the published literature, identifying the comorbidity of functional gastrointestinal disorders in people with fibromyalgia. We discuss the clinical implications, limitations of current research, and areas of interest for future research Methods A systematic review of the databases Medline, Embase, CINAHL and Web of Science was undertaken in June 2019. Results were screened for original articles meeting strict criteria for identification of functional gastrointestinal disorders in adult subjects with fibromyalgia. ResultsFourteen articles were included investigating 1340 subjects with fibromyalgia, 363 healthy controls and 441 subjects with other pathologies. Functional gut disorders were matched to Rome II criteria for reporting and comparison. In addition to increased abdominal pain and functional bloating/gas, irritable bowel of mixed-pattern and constipation-types were more prevalent that diarrhoea-predominant irritable bowel in adults with fibromyalgia. One study reported the range of functional gastrointestinal disorders. Conclusion Existing research has focused on the relationship between irritable bowel syndrome and fibromyalgia, but sub-typing of irritable bowel syndrome is generally overlooked. A strong association with a range of functional gastrointestinal disorders is suggested. Further investigation is needed to determine the prevalence and relevance of the range of functional gastrointestinal disorders in patients with fibromyalgia.

show abstract

“…7 In two independent studies it were estimated that Open access IBS-related absenteeism and presenteeism cost industry £400-£900 8 or to €937-€2108 annually. 9 A diet that is low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) 10 alias a low FODMAP diet (LFD), is an effective dietary intervention for IBS. A blinded and placebo-controlled trial found that approximately three-quarters of patients with IBS benefit from an LF.…”

Section: Introductionmentioning

confidence: 99%

Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial

Yan

Murphy

Genoni

et al. 2020

BMJ Open Gastroenterol

View full text Add to dashboard Cite

IntroductionA diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) is an effective way to reduce gut symptoms in people with irritable bowel syndrome (IBS). This diet reduces the intake of fermentable fibres, leading to changes of the gut microbiota and insufficient fermentation in the large bowel, resulting in reduced production of short-chain fatty acids (SCFAs), such as butyrate, which has unfavourable implications for gut health, sleep and mental health. This study will examine the effect of Fibre-fix, a supplement containing a mix of dietary fibres, on the human gut microbiome composition, fermentative capacity, sleep, quality of life (QOL) and mental health of people with IBS who consume a low FODMAP diet (LFD).Methods and analysisA randomised, double-blind, placebo-controlled, study design is proposed to examine whether Fibre-fix added to an existing LFD may help modulate gastrointestinal function, improve markers of sleep, mental health and promote QOL in patients with IBS. Participants will provide stool and blood samples, daily bowel symptoms diaries and 3-day diet records. Additionally, they will complete validated questionnaires relating to FODMAP intake, sleep, mental health and QOL before and after a 3-week intervention. Gut health will be assessed via faecal microbiome composition, faecal pH and SCFA levels. Alteration of sleep will be recorded using an actigraphy device worn by all participants over the whole study. Multivariate analysis will be used to examine the gut microbiome and repeated measures Analysis of variance (ANOVA) will be used for dependent variables from questionnaires related to bowel symptoms, stool type, sleep, mental health and QOL to assess the differences between intervention and control groups after adjustment for confounding variables.Ethics and disseminationEthics approval was obtained from the Human Research Ethics Committee of Edith Cowan University (2019-00619-YAN). Results will be disseminated in peer-review journal publications, and conference presentations. Participants will be provided with a summary of findings once the study is completed. If Fibre-fix is shown to result in favourable changes in gut microbial composition, SCFA production, sleep and mental well-being without exacerbating symptoms, this will provide additional dietary management options for those with IBS following an LFD.Trial registration numberACTRN12620000032954.

show abstract

Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

Cited by 76 publications

References 36 publications

Healthcare Consumption and Cost Estimates Concerning Swedish Women with Endometriosis

Healthcare Consumption and Cost Estimates Concerning Swedish Women with Endometriosis

A systematic review of the association between fibromyalgia and functional gastrointestinal disorders

Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial

Contact Info

Product

Resources

About